US FDA To Increase Surveillance Of Pharmaceutical Manufacturing Sites In Poor-Quality Countries

Agency revises internal guidance to incorporate statutory requirement for greater scrutiny of drug manufacturing facilities in countries where past experience demonstrates overall quality is low. Revised MAPP also allows for inspection deferral at sites that have superior quality systems.